对门诊 2 型糖尿病患者使用抗糖尿病药物的成本效益分析

Proceeding of International Conference on Science, Health, And Technology Pub Date : 2023-09-23 DOI:10.47701/icohetech.v4i1.3407

Kusumaningtyas Siwi Artini, Tiara Ajeng L, Annisa Kusuma Wardhani

{"title":"对门诊 2 型糖尿病患者使用抗糖尿病药物的成本效益分析","authors":"Kusumaningtyas Siwi Artini, Tiara Ajeng L, Annisa Kusuma Wardhani","doi":"10.47701/icohetech.v4i1.3407","DOIUrl":null,"url":null,"abstract":"Type 2 diabetes Mellitus is a chronic disease that requires lifelong treatment. In the course of the disease, if blood sugar levels are not controlled, it can lead to complications of other diseases. The variety of antidiabetic drugs used in therapy can lead to differences in the cost effectiveness of therapy. The aims of this study is to analyze the cost-effectiveness of antidiabetic therapy in outpatients at Dr. Moewardi Hospital. Data collection in this study was carried out retrospectively using medical records of outpatients with type 2 diabetes mellitus and billing data from the hospital The data obtained were then presented descriptively and the ACER value was calculated for the 2 most widely used drug groups. The results of this study showed that 30 patients received a combination of Insulin Analog (Basal) + Insulin Analog (Prandial/Premixed) and and 11 patients received Insulin Analog (Basal/ Prandial/ Premixed). The percentage effectiveness of combination therapy Insulin Analog (Basal) + Insulin Analog (Prandial/ Premixed) was higher than Insulin Analog (Basal/ Prandial/ Premixed) (83.33 vs 72.72). The ACER value of Insulin Analog (Basal) + Insulin Analog (Prandial/ Premixed) (IDR 13.802,42) is lower than Insulin Analog (Basal/ Prandial/ Premixed) (IDR 18.356). Based on the cost effectiveness table, the combination of Insulin Analog (Basal) + Insulin Analog (Prandial / Premixed) is more effective so that the combination of Insulin Analog (Basal) + Insulin Analog (Prandial / Premixed) is more cost effective than Insulin Analog (Basal / Prandial / Premixed).","PeriodicalId":415761,"journal":{"name":"Proceeding of International Conference on Science, Health, And Technology","volume":"18 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COST – EFFECTIVENESS ANALYSIS OF USING ANTIDIABETIC IN OUTPATIENT WITH TYPE 2 DIABETES MELLITUS\",\"authors\":\"Kusumaningtyas Siwi Artini, Tiara Ajeng L, Annisa Kusuma Wardhani\",\"doi\":\"10.47701/icohetech.v4i1.3407\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Type 2 diabetes Mellitus is a chronic disease that requires lifelong treatment. In the course of the disease, if blood sugar levels are not controlled, it can lead to complications of other diseases. The variety of antidiabetic drugs used in therapy can lead to differences in the cost effectiveness of therapy. The aims of this study is to analyze the cost-effectiveness of antidiabetic therapy in outpatients at Dr. Moewardi Hospital. Data collection in this study was carried out retrospectively using medical records of outpatients with type 2 diabetes mellitus and billing data from the hospital The data obtained were then presented descriptively and the ACER value was calculated for the 2 most widely used drug groups. The results of this study showed that 30 patients received a combination of Insulin Analog (Basal) + Insulin Analog (Prandial/Premixed) and and 11 patients received Insulin Analog (Basal/ Prandial/ Premixed). The percentage effectiveness of combination therapy Insulin Analog (Basal) + Insulin Analog (Prandial/ Premixed) was higher than Insulin Analog (Basal/ Prandial/ Premixed) (83.33 vs 72.72). The ACER value of Insulin Analog (Basal) + Insulin Analog (Prandial/ Premixed) (IDR 13.802,42) is lower than Insulin Analog (Basal/ Prandial/ Premixed) (IDR 18.356). Based on the cost effectiveness table, the combination of Insulin Analog (Basal) + Insulin Analog (Prandial / Premixed) is more effective so that the combination of Insulin Analog (Basal) + Insulin Analog (Prandial / Premixed) is more cost effective than Insulin Analog (Basal / Prandial / Premixed).\",\"PeriodicalId\":415761,\"journal\":{\"name\":\"Proceeding of International Conference on Science, Health, And Technology\",\"volume\":\"18 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Proceeding of International Conference on Science, Health, And Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47701/icohetech.v4i1.3407\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceeding of International Conference on Science, Health, And Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47701/icohetech.v4i1.3407","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

2 型糖尿病是一种需要终身治疗的慢性疾病。在患病过程中，如果血糖水平得不到控制，就会导致其他疾病的并发症。治疗中使用的抗糖尿病药物种类繁多，会导致治疗成本效益的差异。本研究旨在分析 Moewardi 医生医院门诊患者的抗糖尿病治疗成本效益。本研究使用 2 型糖尿病门诊患者的病历和医院的账单数据进行回顾性数据收集，然后以描述性方式呈现所获得的数据，并计算出 2 组最常用药物的 ACER 值。研究结果显示，30 名患者接受了胰岛素类似物（基础）+胰岛素类似物（餐前/预混）联合疗法，11 名患者接受了胰岛素类似物（基础/餐前/预混）联合疗法。胰岛素类似物（基础）+胰岛素类似物（餐前/预混）联合疗法的有效百分比高于胰岛素类似物（基础/餐前/预混）（83.33 vs 72.72）。胰岛素类似物（基础）+胰岛素类似物（餐前/预混）的 ACER 值（13 802 42 印度卢比）低于胰岛素类似物（基础/餐前/预混）（18 356 印度卢比）。根据成本效益表，胰岛素类似物（基础）+胰岛素类似物（餐前/预混）的组合更有效，因此胰岛素类似物（基础）+胰岛素类似物（餐前/预混）的组合比胰岛素类似物（基础/餐前/预混）更具成本效益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

COST – EFFECTIVENESS ANALYSIS OF USING ANTIDIABETIC IN OUTPATIENT WITH TYPE 2 DIABETES MELLITUS

Type 2 diabetes Mellitus is a chronic disease that requires lifelong treatment. In the course of the disease, if blood sugar levels are not controlled, it can lead to complications of other diseases. The variety of antidiabetic drugs used in therapy can lead to differences in the cost effectiveness of therapy. The aims of this study is to analyze the cost-effectiveness of antidiabetic therapy in outpatients at Dr. Moewardi Hospital. Data collection in this study was carried out retrospectively using medical records of outpatients with type 2 diabetes mellitus and billing data from the hospital The data obtained were then presented descriptively and the ACER value was calculated for the 2 most widely used drug groups. The results of this study showed that 30 patients received a combination of Insulin Analog (Basal) + Insulin Analog (Prandial/Premixed) and and 11 patients received Insulin Analog (Basal/ Prandial/ Premixed). The percentage effectiveness of combination therapy Insulin Analog (Basal) + Insulin Analog (Prandial/ Premixed) was higher than Insulin Analog (Basal/ Prandial/ Premixed) (83.33 vs 72.72). The ACER value of Insulin Analog (Basal) + Insulin Analog (Prandial/ Premixed) (IDR 13.802,42) is lower than Insulin Analog (Basal/ Prandial/ Premixed) (IDR 18.356). Based on the cost effectiveness table, the combination of Insulin Analog (Basal) + Insulin Analog (Prandial / Premixed) is more effective so that the combination of Insulin Analog (Basal) + Insulin Analog (Prandial / Premixed) is more cost effective than Insulin Analog (Basal / Prandial / Premixed).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Proceeding of International Conference on Science, Health, And Technology

自引率

0.00%

发文量